BRISPR®

Bacteria platform to deliver RNA and protein

We have a strong preclinical pipeline fully owned and IP-protected. Our engineered bacteria deliver diverse cargos larger than other vehicles can handle, and are equipped with safety switches and other smart controls.

Disease areas

  • Cancer

    • Lead asset RONC1 against pancreatic cancer
  • Genetic diseases

    • Collaboration with large-cap pharma in progress

Targeted

Target the right cells in the right tissues

Selective self-amplification

Enhance efficacy where needed

We welcome additional industry partnerships.  Please contact us for further details.